# A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

> **NCT05275673** · PHASE2 · TERMINATED · sponsor: **Faeth Therapeutics** · enrollment: 7 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Squamous Non-small-cell Lung Cancer
- Squamous Non-Small Cell Neoplasm of Lung
- NFE2L2 Gene Mutation

## Interventions

- **DRUG:** sapanisertib

## Key facts

- **NCT ID:** NCT05275673
- **Lead sponsor:** Faeth Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-21
- **Primary completion:** 2023-01-24
- **Final completion:** 2023-01-24
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Sponsor decision - funding issues
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275673, "A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05275673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*